Latest news with #SLE
Business Insider
5 days ago
- Business
- Business Insider
Super League Enterprise files to sell $20M in common stock for holders
16:50 EDT Super League Enterprise (SLE) files to sell $20M in common stock for holders Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
STV News
5 days ago
- Business
- STV News
Rural businesses praised for ‘extraordinary' help with wildfires, report says
A report has praised rural businesses for their involvement in tackling the recent spate of large wildfires that have devastated parts of Scotland's countryside. Scottish Land & Estates (SLE) published the report on Thursday, which examines the wildfires near Carrbridge and Dava in the Scottish Highlands. The report says 11,827 hectares of moorland were ravaged by the fires in late June. Prepared at the request of Scottish Government officials, the report says extensive resources, manpower and expertise were contributed by at least 33 businesses, including 27 estates. The collective value of specialist firefighting equipment deployed by private land managers is conservatively estimated at £3.1m, with more than 100 employees engaged in the containment effort. PA Media Ross Ewing, director of moorland at SLE, said: 'The Carrbridge and Dava wildfires represent the largest such event in Scotland's history and without the extraordinary intervention of rural businesses, the scale of devastation would have been even greater. 'These land managers brought not only equipment and personnel, but also essential knowledge of the terrain and fire behaviour, much of it honed through generations of safe muirburn practice. Their contribution should be commended, supported and learned from.' The report also says there are gaps in the Scottish Fire and Rescue Service's (SFRS) wildfire response capability, and makes a series of recommendations. They include investment in a fleet of at least 50 SFRS all-terrain vehicles equipped with fogging units, enhanced authority for SFRS commanders to deploy aerial support quickly, urgent improvements in wildfire training and communications for frontline crews, and the establishment of a Scotland-wide integrated fire management strategy. The report also highlights that the licensing framework for muirburn, as introduced through the Wildlife Management and Muirburn Act 2024, could reduce the ability of land managers to conduct fuel load management – a key factor in wildfire prevention. Mr Ewing said: 'If we make it harder for skilled land managers to carry out preventative muirburn, we risk losing the very infrastructure and capability that helped contain these fires. 'Under the recent legislation, there is a 'necessity' test regarding use of muirburn on peatland, and a presumption in favour of other vegetation control methods. 'By amending this to an appropriateness test, it would allow this vital practice of muirburn to be carried out more freely while simultaneously retaining licensed regulatory oversight by government agencies.' Mr Ewing added: 'The Scottish Government must treat these wildfires as a watershed moment. 'That means urgent investment in firefighting infrastructure, better co-ordination between public agencies and rural communities, and a policy environment that empowers land managers, rather than penalising them, for playing their part. 'Without the courage and commitment of those who stepped up during this crisis, the outcome would have been far worse. We owe them our thanks and we owe them action.' Agriculture and connectivity minister Jim Fairlie said: 'We fully understand the concerns over wildfires. Keepers were a massive help to the Scottish Fire and Rescue Service in bringing the recent wildfires under control, and we know estates used their own equipment to help in those efforts. 'That practical help and experience is greatly appreciated by the Scottish Government, as are the views of the wider stakeholder groups who helped to inform our policy decisions as we progressed the Wildlife Management and Muirburn (Scotland) Act 2024. 'During the passage of that Act, we recognised the importance of muirburn in creating firebreaks to help tackle wildfires in some circumstances and the new muirburn licensing scheme allows muirburn for that purpose. 'The Scottish Government is working with SFRS to support full implementation of its wildfire strategy, which will see the continued rollout this year of new equipment, vehicles and personal protective equipment. 'I am grateful to SFRS, the Scottish Gamekeepers Association, and others for their outstanding efforts to keep property and people safe and for taking the time to meet with me this week to reflect on lessons we can learn for future incidents.' SFRS was approached for comment. Get all the latest news from around the country Follow STV News Scan the QR code on your mobile device for all the latest news from around the country
New Straits Times
5 days ago
- Health
- New Straits Times
Vivy Yusof reveals battle with lupus: 'My body is collapsing from inside'
KUALA LUMPUR: Datin Vivy Yusof, co-founder of the e-commerce platform FashionValet, has revealed she is battling the autoimmune disease lupus, also known as Systemic Lupus Erythematosus (SLE). In an Instagram post, Vivy, whose full name is Vivy Sofinas Yusof, 38, said she must live with the condition for the rest of her life and is actively seeking treatment. "Lupus means wolf, which symbolises how frightening this illness is. Essentially, it attacks your body from within, and you may not realise it as it manifests through symptoms such as fatigue, rashes or joint pain. "Stress is the biggest enemy. I thought I was managing my stress well as an entrepreneur since I rarely fall ill and I'm always optimistic, but I didn't realise my body is actually collapsing from inside," she said. Lupus is a chronic autoimmune disease in which the immune system attacks the body's tissues and organs. It can affect anyone, but is most commonly found among women aged between 15 and 50. The disease is reported to impact not only physical health but also mental well-being, often leading to symptoms of anxiety and depression. However, Vivy, who is married to Datuk Fadzarudin Shah Anuar, is grateful the disease was detected, giving her a chance to seek treatment. "I'm thankful I was diagnosed. Now I know how to manage it. "I've been told it's a lifelong condition, which I've come to terms with. Still, I'm constantly exploring treatment options that don't involve long-term steroid use," she said. Vivy has resumed sharing aspects of her life with followers on social media after a brief hiatus. She has created a new Instagram account as a platform to share her personal journey. Through the account, she has opened up about her experience with lupus. Previously, Vivy had set her main Instagram account to private following legal proceedings. Vivy and her husband were charged with an alternative count of criminal breach of trust involving RM8 million in investment funds belonging to Khazanah Nasional Bhd and Permodalan Nasional Bhd six years ago.
Malaysian Reserve
08-07-2025
- Business
- Malaysian Reserve
Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology
The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key factors include increasing clinical success, regulatory approvals, and the ability of these therapies to engage immune cells directly against tumors. Partnerships and investments from major pharmaceutical players are accelerating pipeline development. The bispecific antibody and BiTE market is also expanding beyond oncology into autoimmune and infectious diseases. LAS VEGAS, July 8, 2025 /PRNewswire/ — DelveInsight's Bispecifics/BiTE Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Acute Lymphocytic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma, Multiple Myeloma, Non-small-cell Lung Cancer (NSCLC), Small-cell Lung Cancer (SCLC), Biliary Tract Cancer (BTC), Psoriasis, Rheumatoid Arthritis, Multiple Sclerosis, Systemic Lupus Erythematosus (SLE), Wet Age-related Macular Degeneration (AMD), and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging bispecifics/BiTE, market share of individual therapies, and current and forecasted bispecifics/BiTE market size from 2020 to 2034, segmented into 7MM. Key Takeaways from the Bispecifics/BiTE Market Report As per DelveInsight's analysis, the total market size of bispecifics/BiTE in the 7MM is expected to surge significantly by 2034. The report provides the total potential number of patients in the indications, such as Acute Lymphocytic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma, Multiple Myeloma, Non-small-cell Lung Cancer (NSCLC), Small-cell Lung Cancer (SCLC), Biliary Tract Cancer (BTC), Psoriasis, Rheumatoid Arthritis, Multiple Sclerosis, Systemic Lupus Erythematosus (SLE), Wet Age-related Macular Degeneration (AMD), and others. Leading bispecifics/BiTE companies, such as Aurigene Oncology, Curis, Zenas BioPharma, I-MAB Biopharma, ABL Bio, Bristol Myers Squibb, IMBiologics, Y-Biologics, HK Innoen, Sanofi, Regeneron Pharmaceuticals, and others, are developing novel bispecifics/BiTE that can be available in the bispecifics/BiTE market in the coming years. Some of the key bispecifics/BiTE therapies in the pipeline include CA-170, Obexelimab, Givastomig, IMB-101, SAR446422, Linvoseltamab, and others. Based on pipeline activities, most of the bispecific antibodies are developed in multiple myeloma, followed by NSCLC. In June 2025, BioNTech and Bristol Myers Squibb agreed on the global co-development and co-commercialization of BioNTech's investigational bispecific antibody BNT327 across numerous solid tumor types. Under the agreement, BioNTech and BMS will work jointly to broaden and accelerate the development of this clinical candidate. According to Zenas BioPharma's Q1 2025 report published in May 2025, the company anticipates reporting topline Phase III results for Obexelimab in IgG4-related disease by the end of 2025, 12-week primary endpoint data in RMS in the third quarter of 2025, and 24-week primary endpoint data in SLE in the first half of 2026. In February 2025, Regeneron Pharmaceuticals announced that the US FDA the resubmission of the Biologics License Application (BLA) for linvoseltamab accepted for review for the treatment of adult patients with Relapsed/Refractory multiple myeloma who have received at least four prior lines of therapy or those who received three prior lines of therapy and are refractory to the last line of therapy. The target action date for the FDA decision is July 10, 2025. According to I-MAB Biopharma's Q1 2025 report published in May 2025, the company anticipates presenting data from the givastomig dose expansion cohorts (n = 40) in the first half of 2026, with further development initiatives and data readouts from the Phase Ib study expected through 2027. Additionally, new data from the givastomig dose escalation combination study in US patients will be presented at the European Society of Medical Oncology Gastrointestinal (ESMO GI) Cancers Congress 2025, scheduled for July 2–5 in Barcelona, Spain. In May 2025, Genentech announced two-year follow-up data from the Phase III STARGLO study. The updated data continue to demonstrate the statistically significant and clinically meaningful survival benefit of this off-the-shelf, fixed-duration Columvi combination for people with R/ DLBCL who have received at least one prior line of therapy and are not candidates for autologous stem cell transplant (ASCT). Discover which indication is expected to grab the major bispecifics/BiTE market share @ Bispecifics/BiTE Market Report Bispecifics/BiTE Market Dynamics The bispecific antibody and BiTE market is experiencing strong momentum, driven by rapid advancements in immuno-oncology and increasing demand for precision biologics. These modalities are designed to simultaneously bind two different antigens or epitopes, commonly one on a tumor cell and the other on an immune effector cell, such as a T-cell, thereby redirecting immune activity toward malignant cells. Their ability to provide targeted immune activation while minimizing systemic toxicity positions them as highly attractive therapeutic options, particularly for difficult-to-treat cancers and hematological malignancies. Market growth is being fueled by a combination of technological innovation and clinical validation. Companies are investing heavily in next-generation bispecific platforms that offer improved stability, manufacturability, and half-life extension. Major pharmaceutical players, as well as emerging biotech firms, are advancing robust pipelines of bispecifics and BiTEs, with several candidates achieving regulatory approvals in recent years. The entry of these agents has set a precedent, increasing investor confidence and accelerating deal-making activity, including strategic collaborations and licensing agreements. Despite the enthusiasm, the bispecifics/BiTE market faces key challenges. Manufacturing complexities, immunogenicity risks, and potential for cytokine release syndrome remain technical and clinical hurdles. Additionally, the crowded competitive landscape necessitates differentiation, either through novel targets (e.g., B7-H3, DLL3, CLDN6) or superior clinical outcomes. Pricing pressures and reimbursement considerations also loom large, particularly as more therapies enter the market and stakeholders demand cost-effective value delivery. In summary, the bispecific and BiTE market represents one of the most dynamic frontiers in biologics. With many candidates in preclinical and clinical development globally, the next decade is likely to see continued maturation of the field, consolidation among players, and deeper integration of bispecifics into standard-of-care treatment paradigms. Strategic investments, patient-centric development, and continuous innovation will be critical to sustaining long-term growth. Bispecifics/BiTE Treatment Market Bispecific antibodies are designed to address complex, multifactorial diseases by simultaneously targeting two distinct disease-related molecules with a single therapeutic agent. Most approved bispecifics are used in oncology, particularly for conditions like multiple myeloma and diffuse large B-cell lymphoma (DLBCL). Outside of oncology, only two, HEMLIBRA and VABYSMO, have been approved for treating hemophilia A, neovascular (wet) age-related macular degeneration, and diabetic macular edema. Additionally, KIMMTRAK, a bispecific molecule, has received approval specifically for uveal melanoma. REMOVAB, the world's first approved bispecific antibody, was developed to treat malignant ascites associated with solid tumors and received approval from the EMA. However, it was withdrawn from the market in 2017 due to commercial considerations. ZIIHERA is a bispecific antibody that targets HER2 by binding to two distinct extracellular domains on the receptor. In November 2024, the U.S. FDA granted accelerated approval for ZIIHERA (50 mg/mL for IV injection) for use in adults with previously treated, unresectable, or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC). Zanidatamab, the molecule behind ZIIHERA, is also under evaluation in various clinical trials as a targeted therapy for solid tumors. These include Phase III studies for gastroesophageal adenocarcinoma (GEA) and metastatic breast cancer (mBC), as well as Phase II trials for colorectal and breast cancers. The drug was originally developed by Zymeworks and is now being advanced by Jazz Pharmaceuticals and BeiGene through licensing agreements. Jazz holds commercialization rights for the U.S., Europe, Japan, and all regions except Asia-Pacific territories already licensed by Zymeworks to BeiGene (excluding Japan, but including the rest of Asia, Australia, and New Zealand). In April 2025, Jazz announced its participation at the ASCO annual meeting, where three abstracts related to zanidatamab were accepted for presentation. Furthermore, the European Medicines Agency's CHMP issued a positive opinion recommending conditional marketing authorization of zanidatamab monotherapy for adults with previously treated, unresectable, locally advanced or metastatic HER2-positive (IHC 3+) BTC. COLUMVI is a bispecific antibody designed to engage CD20 and CD3, featuring a unique 2:1 structural configuration. It brings T cells into proximity with malignant B cells, making it effective in targeting cancers such as diffuse large B-cell lymphoma (DLBCL). In June 2023, the FDA granted accelerated approval to COLUMVI for use in patients with relapsed or refractory DLBCL (not otherwise specified) or large B-cell lymphoma (LBCL) that has transformed from follicular lymphoma, following at least two prior systemic treatments. Learn more about the FDA-approved bispecifics/BiTE therapies @ Bispecifics/BiTE Drugs Key Emerging Bispecifics/BiTE and Companies Several key players, including Aurigene Oncology/Curis (CA-170), I-MAB Biopharma/ABL Bio/Bristol Myers Squibb (Givastomig), IMBiologics/Y-Biologics/HK Innoen (IMB-101), Regeneron Pharmaceuticals (Linvoseltamab), Sanofi (SAR446422), Zenas BioPharma (Obexelimab), and others, are involved in developing drugs for Bispecifics/BiTE for various indications such as NSCLC, Bladder and Kidney Cancers, IgG4-RD, RMS, SLE, multiple sclerosis, and others. CA-170 is an orally administered, first-in-class small molecule with strong activity. It selectively inhibits PD-L1 and VISTA, both of which are immune checkpoint proteins that suppress immune responses. The compound is currently undergoing Phase III clinical trials for non-small cell lung cancer (NSCLC) as well as bladder and kidney cancers. In February 2020, Curis revised its collaboration and licensing agreement with Aurigene Discovery Technologies. The updated terms granted Aurigene development and commercialization rights for CA-170 across Asia, expanding on its original rights in India and Russia. Curis retained exclusive rights to the drug in the United States, Europe, and other global markets and is eligible to receive royalties from sales in Asia. The original partnership between Curis and Aurigene began in 2015. Givastomig (also referred to as TJ-CD4B/ABL111 or TJ033721) is a bispecific antibody engineered to target Claudin 18.2 (CLDN18.2) on tumor cells and activate T-cells through 4-1BB in a tumor-restricted manner. It is designed to engage tumor cells expressing varying levels of CLDN18.2, commonly found in gastric and pancreatic cancers, and locally stimulate T-cell activity within the tumor microenvironment. In September 2024, I-Mab Biopharma shared results from a Phase I trial of givastomig in patients with CLDN18.2-positive advanced gastroesophageal cancer. The therapy was well tolerated at doses up to 15 mg/kg administered biweekly and showed promising clinical activity in patients who had previously undergone multiple treatments. These patients exhibited a broad range of CLDN18.2 expression. Earlier, in March 2022, the FDA granted givastomig Orphan Drug Designation for the treatment of gastric and gastroesophageal junction cancers. The anticipated launch of these emerging therapies are poised to transform the bispecifics/BiTE market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the bispecifics/BiTE market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about bispecifics/BiTE clinical trials, visit @ Bispecifics/BiTE Treatment Drugs Bispecifics/BiTE Overview Bispecific antibodies, including Bispecific T-cell Engagers (BiTEs), represent an innovative class of immunotherapies designed to harness the immune system to target and destroy cancer cells more precisely. Unlike conventional monoclonal antibodies, bispecifics are engineered to recognize and bind to two different antigens simultaneously. One arm typically targets a tumor-associated antigen on cancer cells, while the other engages a molecule on immune cells, most commonly CD3 on T cells. This dual targeting brings T cells into close proximity with tumor cells, triggering T-cell activation and cytotoxicity, even without the need for antigen presentation or co-stimulation. BiTEs are a specific subset of bispecifics characterized by their compact size and lack of an Fc region, enabling better tissue penetration and faster pharmacokinetics. The most well-known example is blinatumomab, approved for treating certain types of B-cell acute lymphoblastic leukemia. As research expands, next-generation BiTEs and bispecifics are being developed to improve half-life, reduce off-target effects, and address solid tumors, traditionally more challenging for immunotherapy. Their modular design also enables customization to different tumor types and immune targets, making them a versatile and rapidly advancing segment of oncology therapeutics. Bispecifics/BiTE Epidemiology Segmentation The bispecifics/BiTE market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Cases in Selected Indications for Bispecifics/BiTE Total Eligible Patient Pool in Selected Indications for Bispecifics/BiTE Total Treated Cases in Selected Indications for Bispecifics/BiTE Bispecifics/BiTE Report Metrics Details Study Period 2020–2034 Bispecifics/BiTE Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Indications Covered in the Report Acute Lymphocytic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma, Multiple Myeloma, Non-small-cell Lung Cancer (NSCLC), Small-cell Lung Cancer (SCLC), Biliary Tract Cancer (BTC), Psoriasis, Rheumatoid Arthritis, Multiple Sclerosis, Systemic Lupus Erythematosus (SLE), Wet Age-related Macular Degeneration (AMD), and others Key Bispecifics/BiTE Companies Aurigene Oncology, Curis, Zenas BioPharma, I-MAB Biopharma, ABL Bio, Bristol Myers Squibb, IMBiologics, Y-Biologics, HK Innoen, Sanofi, Regeneron Pharmaceuticals, Zymeworks, Genentech, Genmab, Pfizer, Johnson & Johnson Innovative Medicine, AstraZeneca, and others Key Bispecifics/BiTE Therapies CA-170, Obexelimab, Givastomig, IMB-101, SAR446422, Linvoseltamab, ZIIHERA, COLUMVI, EPKINLY, LUNSUMIO, ELREXFIO, VABYSMO, TECVAYLI, SAPHNELO, OCREVUS, and others Scope of the Bispecifics/BiTE Market Report Bispecifics/BiTE Therapeutic Assessment: Bispecifics/BiTE current marketed and emerging therapies Bispecifics/BiTE Market Dynamics: Conjoint Analysis of Emerging Bispecifics/BiTE Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Bispecifics/BiTE Market Access and Reimbursement Discover more about bispecifics/BiTE therapies in development @ Bispecifics/BiTE Clinical Trials Table of Contents 1 Key Insights 2 Report Introduction 3 Key Highlights Of The Report 4 Executive Summary Of Bispecifics/BiTE 5 Key Events 6 Epidemiology And Market Forecast Methodology 7 Bispecific/BiTE Market Overview At A Glance 7.1 Market Share (%) Distribution of Bispecifics/BiTE by Therapies in 2024 7.2 Market Share (%) Distribution of Bispecifics/BiTE by Therapies in 2034 7.3 Market Share (%) Distribution of Bispecifics/BiTE by Indications in 2024 7.4 Market Share (%) Distribution of Bispecifics/BiTE by Indications in 2034 8 Background And Overview 8.1 Introduction 8.2 Treatment 8.3 FDA-Approved Bispecifics/BiTE Antibodies 9 Epidemiology And Patient Population 9.1 Key Findings 9.2 Assumptions And Rationale 9.3 Total Cases of Selected Indication for Bispecifics/BiTE in the 7MM 9.4 The eligible pool of Indications for Bispecific/BiTE Antibodies in the 7MM 9.5 Treatable Cases by Indication for Bispecific/BiTE Antibodies in the 7MM 10 Marketed Drugs 10.1 Key Competitors 10.2 ZIIHERA (zanidatamab): Zymeworks 10.2.1 Product Description 10.2.2 Regulatory Milestones 10.2.3 Other Developmental Activities 10.2.4 Clinical Development 10.2.4.1 Clinical Trial Information 10.2.5 Safety and Efficacy 10.2.6 Analyst Views 10.3 COLUMVI (glofitamab): Roche 10.3.1 Product Description 10.3.2 Regulatory Milestones 10.3.3 Other Developmental Activities 10.3.4 Clinical Development 10.3.4.1 Clinical Trial Information 10.3.5 Safety and Efficacy 10.3.6 Analyst Views List to be continued… 11 Emerging Drugs 11.1 Key Competitors 11.2 CA-170: Aurigene Oncology and Curis 11.2.1 Product Description 11.2.2 Other Development Activities 11.2.3 Clinical Development 11.2.3.1 Clinical Trials Information 11.2.4 Safety and Efficacy 11.2.5 Analyst Views 11.3 Givastomig: I-MAB Biopharma, ABL Bio, and Bristol Myers Squibb 11.3.1 Product Description 11.3.2 Other Development Activities 11.3.3 Clinical Development 11.3.3.1 Clinical Trials Information 11.3.4 Safety and Efficacy 11.3.5 Analyst Views List to be continued… 12 Bispecifics/BiTE: The 7MM Analysis 12.1 Key Findings 12.2 Market Outlook 12.3 Conjoint Analysis 12.4 Key Market Forecast Assumptions 12.4.1 Cost Assumptions and Rebates 12.4.2 Pricing Trends 12.4.3 Analogue Assessment 12.4.4 Launch Years and Therapy Uptake 12.5 Total Market Size of Bispecifics/BiTE in the 7MM 12.6 United States Market 12.6.1 Market Size of Bispecifics/BiTE By Indications in the United States 12.6.2 Market Size By Therapies in the United States 12.7 EU4 and the UK Market 12.7.1 Market Size of Bispecifics/BiTE By Indications in EU4 and the UK 12.7.2 Market Size By Therapies in EU4 and the UK 12.8 Japan Market 12.8.1 Market Size of Bispecifics/BiTE By Indications in Japan 12.8.2 Market Size By Therapies in Japan 13 Unmet Needs Of Bispecifics/BiTE 14 SWOT Analysis Of Bispecifics/BiTE 15 KOL Views Of Bispecifics/BiTE 16 Market Access and Reimbursement 16.1 United States 16.1.1 Centre for Medicare & Medicaid Services (CMS) 16.2 EU4 and the UK 16.2.1 Germany 16.2.2 France 16.2.3 Italy 16.2.4 Spain 16.2.5 United Kingdom 16.3 Japan 16.3.1 MHLW 17 Appendix 17.1 Bibliography 17.2 Report Methodology 18 DelveInsight Capabilities 19 Disclaimer 20 About DelveInsight Related Reports Non-Small Cell Lung Cancer Market Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies, including AstraZeneca, Boehringer Ingelheim, Pfizer, Takeda, Johnson & Johnson Innovative Medicine, Eli Lilly and Company, Merck, Bristol-Myers Squibb, Roche, Shanghai Henlius Biotech, AbbVie, Daiichi Sankyo, Nuvation Bio, PDC*line Pharma, Moderna Therapeutics, Pfizer, GSK, Gilead Sciences, BieGene, Nuvalent, among others. Small Cell Lung Cancer Market Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SCLC companies, including Ascentage Pharma, Merck & Co., AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee's Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics, among others. Diffuse Large B-cell Lymphoma Market Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key DLBCL companies, including AbbVie, Genmab, Merck, Roche, Xencor, Janssen, Denovo Biopharma, Calithera Biosciences, IMV, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, Debiopharm, Seagen, Takeda, AstraZeneca, Gilead Sciences, among others. Multiple Myeloma Market Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple myeloma companies, including Sanofi, Karyopharm Therapeutics, AbbVie, Takeda Pharmaceutical, Celgene, Bristol-Myers Squibb, RAPA Therapeutics, Pfizer, Array Biopharma, Cellectar Biosciences, BioLineRx, Celgene, Aduro Biotech, ExCellThera, Janssen Pharmaceutical, Precision BioSciences, Takeda, Glenmark (Ichnos Sciences SA), Poseida Therapeutics, Molecular Partners AG, Chipscreen Biosciences, AbbVie, Genentech (Roche), Janssen Biotech, Nanjing Legend Biotech, Merck Sharp & Dohme Corp., among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us Shruti Thakur info@ +14699457679 Logo: View original content:
Time of India
01-07-2025
- Health
- Time of India
GMCH docs save 7-yr-old with rare pacemaker op
Guwahati: A team of doctors at Gauhati Medical College and Hospital (GMCH) successfully implanted a life-saving pacemaker on a seven-year-old girl suffering from complete heart block. Tired of too many ads? go ad free now Cardiologists say this condition occurs in one among 22,000 live births. According to the doctors, this disease is very rare, especially in children as young as seven years old. Dr Pranab Jyoti Bhattacharya, professor of cardiology at GMCH who led the team of doctors, said, "Congenital complete heart block has an incidence rate of only 0.006%. That is almost one in 22,000 live births. So it is that rare." He added that when the complete heart block in the girl, identified as Arjina Begum, was detected and she was admitted to GMCH about a week ago, the doctors had no other option but to conduct the procedure as soon as possible, considering the high possibility of mortality in such cases. "The treatment for her ailment was the implantation of a permanent pacemaker. Today, we performed the pacemaker implantation under general anaesthesia successfully," he said, adding, the girl is recovering well. Doctors said it is very difficult to pinpoint the cause of the disease. However, certain autoimmune diseases in the mother, such as systemic lupus erythematosus (SLE), have some association with complete heart block in up to 3% of patients. In this case, the mother of the child did not have any history of SLE during her pregnancy, doctors said. "The most important thing is that if a permanent pacemaker is implanted, she will have a near-normal life with it," he added. Dr Bhattacharya was assisted by his DM cardiology students and junior faculty members, while the cardiac anaesthesia team was headed by Dr Madhurjya Bujarbaruah. The child is from Sontoli in Kamrup district. Tired of too many ads? go ad free now The procedure was done free of cost under Rashtriya Bal Swasthya Karyakram. In a govt facility, such a procedure normally costs about Rs 1 lakh. In private hospitals, it costs about Rs 3 lakh. Arjina's father Abul Kalam Azad, a farmer, said the problem was detected at a govt hospital in Boko town of Kamrup district over a year ago after she fainted at home one day. He added that the medicines prescribed by the doctors in Boko did not work and she again fainted in school one day. "Of late, she was telling us that she felt as if a fish is hitting her in the chest. It was severe pain. Then we decided to bring her to GMCH where doctors told us to get ready for the procedure. All credit to GMCH doctors for giving a new life to our child," said Abul. According to doctors, normally, in children with congenital complete heart block, some may have associated structural heart disease, while others may have a normal heart. "This complete heart block is basically an electrical problem of the heart. If it is associated with other structural heart diseases, then the outcome is very poor. In our patient, echocardiography was done, and the rest of her heart was normal. There was no structural heart disease. However, her heart rate was very low, almost 35/40 per minute, which is abnormal. She was in the high-risk category, and mortality is very high if such a condition is not treated by implanting a permanent pacemaker," Bhattacharya said.
